Skip to main content

Robin Sherrington's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Sep 2, 2022

Accession no.
0001209191-22-048508
Filed
Sep 2, 2022
Trade date
Aug 31-Sep 1, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.50M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Robin SherringtonCIK 0001619962Officer (EVP, Strategy & Innovation)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 31, 2022Common SharesMOption exerciseAcquired+17,488$2.67+$46,692.9634,720Direct
Aug 31, 2022Common SharesMOption exerciseAcquired+5,000$4.75+$23,75039,720Direct
Aug 31, 2022Common SharesFTax withholdingDisposed−1,572$37.86F1−$59,515.9238,148Direct
Aug 31, 2022Common SharesSSaleDisposed−21,352$38.57F2−$823,546.6416,796Direct
Sep 1, 2022Common SharesMOption exerciseAcquired+50,000$4.75+$237,50066,796Direct
Sep 1, 2022Common SharesFTax withholdingDisposed−6,121$38.81F3−$237,556.0160,675Direct
Sep 1, 2022Common SharesSSaleDisposed−35,103$38.03F4−$1,334,967.0925,572Direct
Sep 1, 2022Common SharesSSaleDisposed−8,776$38.80F5−$340,508.816,796Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 31, 2022Common SharesMOption exerciseDisposed−17,488$0.00$00Direct
Aug 31, 2022Common SharesMOption exerciseDisposed−5,000$0.00$00Direct
Sep 1, 2022Common SharesMOption exerciseDisposed−50,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the closing price of the Company's common shares on August 30, 2022 for purposes of net settlement calculations.

Referenced by the price of 1 transaction in Table I.

F2

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F3

Represents the closing price of the Company's common shares on August 31, 2022 for purposes of net settlement calculations.

Referenced by the price of 1 transaction in Table I.

F4

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.44 to $38.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.73 to $38.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)